

Chapter 73

REFERENCES

1. Mokdad A, Marks J, Stroup D, Gerberding J. Actual causes of death in the United States in 2000. *JAMA*. 2004;291:1238-1245.
2. Moore F, McKinley B, Moore E. The next generation of shock resuscitation. *Lancet*. 2004;363:1988-1996.
3. Gelman S. Venous function and central venous pressure. *Anesthesiology*. 2008;108:735-738.
4. Spahn D, Rossaint R. Coagulopathy and blood component transfusion in trauma. *Br J Anaesth*. 2005;95:130-139.
5. Rhee P, Kustova E, Alam H. Searching for the optimal resuscitation method: recommendations for the initial fluid resuscitation of combat casualties. *J Trauma*. 2003;54:552-562.
6. Bickell W, Wall M, Pepe P, et al. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating injuries. *N Engl J Med*. 1994;331:1105-1109.
7. Marik P, Corwin HL. Acute lung injury following blood transfusion: expanding the definition. *Crit Care Med*. 2008;36:3080-3086.
8. Vlaar APJ, Binnekade JM, Prins D, et al. Risk factors and outcomes of transfusion-related acute lung injury in the critically ill: a nested case-control study. *Crit Care Med*. 2010;38:771-778.
9. Lin E, Calvano S, Lowry S. Inflammatory cytokines and cell response in surgery. *Surgery*. 2000;127:117-126.
10. Katzenstein A, Asken F. Acute lung injury patterns: diffuse alveolar damage, acute interstitial pneumonia, bronchiolitis obliterans-organizing pneumonia. In: Katzenstein AAF, ed. *Surgical Pathology of the Non-Neoplastic Lung Diseases*. 2nd ed. Philadelphia, PA: WB Saunders; 1990:9-56.
11. Ware L, Matthay M. The acute respiratory distress syndrome. *N Engl J Med*. 2000;342:1334-1349.
12. Kellum JA. Acute kidney injury. *Crit Care Med*. 2008;36:s141-s145.
13. Barrantes F, Tian J, Vazquez R, et al. Acute kidney injury criteria predict outcomes of critically ill patients. *Crit Care Med*. 2008;36:1397-1403.
14. Jakob SM, Takala J. Gut perfusion in the critically ill. *Intensive Care Med*. 2000;26:813-815.
15. El-Menyar A, Ayman A. The resuscitation outcome: revisit the story of the stony heart. *Chest*. 2005;128:2835-2846.
16. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. *Physiol Rev*. 1999;79:609-634.
17. Heusch G, Schulz R, Rahimtoola S. Myocardial hibernation: a delicate balance. *Am J Physiol*. 2005;288:H984-H999.
18. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. *N Engl J Med*. 1985;312:159-163.
19. Gonzalez D. Crush syndrome. *Crit Care Med*. 2005;33:S34-S41.
20. Kupiec-Weglinski J, Busuttill R. Ischemia and reperfusion injury in liver transplantation. *Transplant Proc*. 2005;37:1653-1656.
21. Seal J, Gewertz B. Vascular dysfunction in ischemia-reperfusion injury. *Ann Vasc Surg*. 2005;19:572-584.
22. Baudouin S. Lung injury after thoracotomy. *Br J Anaesth*. 2003;91:132-142.
23. Hamvas A, Park C, Palazzo R, et al. Modifying pulmonary ischemia-reperfusion injury by altering ventilatory strategies during ischemia. *J Appl Physiol*. 1992;73:2112-2119.
24. Calle E, Thun M, Petrelli J, Rodriguez C, Heath C. Body-mass index and mortality in a prospective cohort of U.S. adults. *N Engl J Med*. 1999;341:1097-1105.
25. Brown C, Neville A, Rhee P, Salim A, Velmahos G, Demetriades D. The impact of obesity on the outcomes of 1,153 critically ill injured blunt trauma patients. *J Trauma*. 2005;59:1048-1051.
26. Ei-Solh A. Clinical approach to the critically ill, morbidly obese patient. *Am J Respir Crit Care Med*. 2004;169:557-561.
27. Erstad B. Dosing of medications in morbidly obese patients in the intensive care unit. *Intensive Care Med*. 2004;30:18-32.
28. Vincent J-L, Sakr Y, Sprung C, et al. Sepsis in European intensive care units: results of the SOAP study. *Crit Care Med*. 2006;34:344-353.
29. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med*. 2001;29:1303-1310.
30. Bateman BT, Schmidt U, Berman M, Bittner EA. Temporal trends in the epidemiology of severe postoperative sepsis after elective surgery. *Anesthesiology*. 2010;112:917-925.
31. Osmon S, Warren D, Seiler S, Shannon W, Fraser P, Kollef M. The influence of infection on hospital mortality for patients requiring more than 48 hours of intensive care. *Chest*. 2003;124:1021-1029.
32. Levy M, Fink M, Marshall J, et al. 2001 SCCM/EISCM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Crit Care Med*. 2003;31:1250-1256.
33. Defres S, Marwick C, Natwhani D. MRSA as a cause of lung infection including airway infection, community-acquired pneumonia, and hospital-acquired pneumonia. *Eur Respir J*. 2010;34:1470-1476.

34. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/ncidod/dhqp/pdf/nhsn_documents.html.
35. Centers for Disease Control and Prevention Web site. <http://www.cdc.gov/ncidod/dhqp/pdf/nnis/NosInfDefinitions.pdf>.
36. Edwards JR, Peterson KD, Andrus ML, et al. National Healthcare Safety Network (NHSN) report, data summary for 2006 through 2007, issued November 2008. *Am J Infect Control*. 2008;36:609-626.
37. American Thoracic Society. Guidelines for the management of adults with hospital- acquired, ventilator- associated, and hospital- associated pneumonia. *Am J Respir Crit Care Med*. 2005;171:388-416.
38. Peleg AY, Hooper DC. Hospital- acquired infections due to gram- negative bacteria. *N Engl J Med*. 2010;362:1804-1813.
39. Kola A, Schwab F, Barwolff S, et al. Is there an association between nosocomial infections rates and bacterial cross transmission? *Crit Care Med*. 2010;38:46-50.
40. Dezfulian C, Shojania K, Collard HR, et al. Subglottic secretion drainage for preventing ventilator-associated pneumonia: a meta-analysis. *Am J Med*. 2005;118:11-18.
41. Institute for Healthcare Improvement Web site. 5 Million Lives Campaign. <http://www.ihf.org/IHI/Programs/Campaign/>
42. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter- related bloodstream infections. *N Engl J Med*. 2006;355:2725-2732.
43. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. *Nature*. 2010;464(7285):104-107.
44. Cuthbertson D. Intensive care metabolic response to injury. *Br J Surg*. 1970;57:718-721.
45. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. *N Engl J Med*. 2003;348:138-150.
46. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. *N Engl J Med*. 1999;340:448-454.
47. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. *Nat Immunol*. 2001;2:675-680.
48. Thomas L. Germs. *N Engl J Med*. 1972;287:553-555.
49. Bone R. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. *Crit Care Med*. 1996;24:163-172.
50. Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. *N Engl J Med*. 1987;317:653-658.
51. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. *N Engl J Med*. 1996;334:1697-1702.
52. Fisher CJ Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. *JAMA*. 1994;271:1836-1843.
53. Herd J. Cardiovascular response to stress. *Physiol Rev*. 1991;71:305-330.
54. Tracey K. The inflammatory reflex. *Nature*. 2002;420:853-859.
55. Borovikova L. Role of the vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. *Nature*. 2000;405:458-462.
56. Wilmore D. From Cuthbertson to fast-track surgery: 70 years of progress in reducing stress in surgical patients. *Ann Surg*. 2002;236:643-648.
57. Van den Berghe G. Novel insights into the neuroendocrinology of critical illness. *Eur J Endocrinol*. 2000;143:1-13.
58. Cooper M, Stewart P. Corticosteroid insufficiency in acutely ill patients. *N Engl J Med*. 2003;348:727-734.
59. Annane D, Sebille V, Troche G, et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. *JAMA*. 2000;283:1038-1045.
60. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. *JAMA*. 2002;288:862-871.
61. Sprung C, Annane D, Keh D, et al. (the CORTICUS Study Group). Hydrocortisone therapy for patients with septic shock. *N Engl J Med*. 2008;358:111-124.
62. Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. *N Engl J Med*. 2004;350:1629-1638.
63. Landry D, Levin H, Gallant E, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. *Circulation*. 1997;95:1122-1125.
64. Russell J, Walley KR, Singer J, et al. (VASST Investigators). Vasopressin versus norepinephrine infusion in patients with septic shock. *N Engl J Med*. 2008;358:877-887.
65. Gordon AC, Russell JA, Walley KR, et al. (VASST Investigators). The effects of vasopressin on acute kidney injury in septic shock. *Intensive Care Med*. 2010;36:83-91.
66. Lipshutz AKM, Gropper MA. Perioperative glycemic control. *Anesthesiology*. 2009;110:408-421.
67. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. *N Engl J Med*. 2001;345:1359-1367.
68. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. *N Engl J Med*. 2006;354:449-461.
69. The NICE-SUGAR Study investigators. Intensive versus Conventional Glucose Control in Critically Ill Patients. *N Engl J Med*. 2009;360:1283-1297.
70. Russell J, Phang P. The oxygen delivery/consumption controversy. Approaches to management of the critically ill patient. *Am J Respir Crit Care Med*. 1994;149:533-537.
71. Hack C, Zeerleder S. The endothelium in sepsis: source of and target for inflammation. *Crit Care Med*. 2001;29:S21-S27.
72. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. *Nat Rev Immunol*. 2008; 8:776-787.
73. Schouten M, Wiersinga WJ, Levi M, et al. Inflammation, endothelium, and coagulation in sepsis. *J Leukoc Biol*. 2008;83:536.
74. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. *Blood*. 2003;101:3675.
75. McGill S, Ahmed N, Christou N. Endothelial cells: role in infection and inflammation. *World J Surg*. 1998;22:171-178.
76. Kumaret P, Shen Q, Pivetti CD, et al. Molecular mechanisms of endothelial hyperpermeability: implications in inflammation. *Expert Rev Mol Med*. 2009;11:e19.
77. Butcher E. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. *Cell*. 1991;67:1033-1036.
78. Springer T. Adhesion receptors of the immune system. *Nature*. 1990;346:425-434.

79. Madoiwa S, Nunomiya S, Ono T, et al. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. *Int J Hematol.* 2006;84:398-405.
80. Prabhakaran P, Ware LB, White KE, et al. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. *Am J Physiol Lung Cell Mol Physiol.* 2003;285:L20-28.
81. Ware LB, Matthay MA, Parsons PE, et al. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. *Crit Care Med.* 2007;35:1821-1828.
82. Levi M, Cate HT. Disseminated intravascular coagulation. *N Engl J Med.* 1999;341:586-592.
83. Warren B, Eid A, Singer P, et al. High-dose anti-thrombin III in severe sepsis. A randomized controlled trial. *JAMA.* 2001;286:1869-1878.
84. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. *N Engl J Med.* 2001;344:699-709.
85. Vincent J-L, Zhang H, Preiser J-C. Effects of nitric oxide in septic shock. *Am J Respir Crit Care Med.* 2000;161:1781-1785.
86. Wanaceck M, Weitzberg E, Rudehill A, et al. The endothelium system in septic and endotoxic shock. *Eur J Pharmacol.* 2000;407:1-15.
87. Kirov M, Evgenov O, Evgenov N, et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. *Crit Care Med.* 2001;29:1860-1867.
88. Avontuur J, Nolthenius R, van Bodegom J, et al. Prolonged inhibition of nitric oxide synthesis in severe septic shock: a clinical study. *Crit Care Med.* 1998;26:660-667.
89. Lopez A, Lorente J, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide inhibitor 546C88: effect on survival in patients with septic shock. *Crit Care Med.* 2004;32:21-30.
90. Beal A, Cerra F. Multiple organ failure syndrome in the 1990s. Systemic inflammatory response and organ dysfunction. *JAMA.* 1994;271:226-233.
91. Clowes G, Hirsch E, George B, et al. Survival from sepsis. The significance of altered protein metabolism regulated by proteolysis inducing factor, the circulating cleavage product of interleukin-1. *Ann Surg.* 1985;202:446-458.
92. Herndon D, Hart D, Wolf S, et al. Reversal of catabolism by beta-blockade after severe burns. *N Engl J Med.* 2001;345:1223-1229.
93. Pullicino EA, Carli F, Poole S, et al. The relationship between the circulating concentrations of interleukin 6 (IL-6), tumor necrosis factor (TNF) and the acute phase response to elective surgery and accidental injury. *Lymphokine Res.* 1990;9:231-238.
94. Krohn CD, Reikeras O, Aasen AO. The cytokines IL-1beta and IL-1 receptor antagonist, IL-2 and IL-2 soluble receptor-alpha, IL-6 and IL-6 soluble receptor, TNF-alpha and TNF soluble receptor I, and IL10 in drained and systemic blood after major orthopaedic surgery. *Eur J Surg.* 1999;165:101-109.
95. Cinat M, Waxman K, Vaziri ND, et al. Soluble cytokine receptors and receptor antagonists are sequentially released after trauma. *J Trauma.* 1995;39:112-118; discussion 118-120.
96. Mokart D, Capo C, Blache JL, et al. Early postoperative compensatory anti-inflammatory response syndrome is associated with septic complications after major surgical trauma in patients with cancer. *Br J Surg.* 2002;89:1450-1456.
97. Keel M, Trentz O. Pathophysiology of polytrauma. *Injury.* 2005;36:691-709.
98. Wright SD, Ramos RA, Tobias PS, et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. *Science.* 1990;249:1431-1433.
99. Fenton MJ, Golenbock DT. LPS-binding proteins and receptors. *J Leukoc Biol.* 1998;64:25-32.
100. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. *Science.* 1998;282:2085-2088.
101. Rock F, Hardiman G, Timans J, et al. A family of human receptors structurally related to *Drosophila* toll. *Proc Natl Acad Sci U S A.* 1998;95:588-593.
102. Sarkar SN, Smith HL, Rowe TM, Sen GC. Double-stranded RNA signaling by toll-like receptor 3 requires specific tyrosine residues in its cytoplasmic domain. *J Biol Chem.* 2003;278:4393-4396.
103. Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by toll-like receptor 5. *Nature.* 2001;410:1099-1103.
104. Hemmi H, Takeuchi O, Kawai T, et al. A toll-like receptor recognizes bacterial DNA. *Nature.* 2000;408:740-745.
105. Hajjar AM, O'Mahony DS, Ozinsky A, et al. Cutting edge: functional interactions between toll-like receptor (TLR) 2 and TLR1 or TLR6 in response to phenol-soluble modulin. *J Immunol.* 2001;166:15-19.
106. Lederer JA, Rodrick ML, Mannick JA. The effects of injury on the adaptive immune response. *Shock.* 1999;11:153-159.
107. Meakins JL, Pietsch JB, Bubenick O, et al. Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma. *Ann Surg.* 1977;186:241-250.
108. Ertel W, Kremer JP, Kenney J, et al. Downregulation of proinflammatory cytokine release in whole blood from septic patients. *Blood.* 1995;85:1341-1347.
109. Ochoa JB, Makarenkova V. T lymphocytes. *Crit Care Med.* 2005;33:S510-513.
110. Pellegrini JD, De AK, Kodys K, et al. Relationships between T lymphocyte apoptosis and anergy following trauma. *J Surg Res.* 2000;88:200-206.
111. Heidecke CD, Hensler T, Weighardt H, et al. Selective defects of T lymphocyte function in patients with lethal intraabdominal infection. *Am J Surg.* 1999;178:288-292.
112. Wahl SM, Swisher J, McCartney-Francis N, Chen W. TGF-beta: the perpetrator of immune suppression by regulatory T cells and suicidal T cells. *J Leukoc Biol.* 2004;76:15-24.
113. Menger MD, Vollmar B. Surgical trauma: hyperinflammation versus immunosuppression? *Langenbecks Arch Surg.* 2004;389:475-484.
114. Murphy TJ, Choileain NN, Zang Y, et al. CD4⁺ CD25⁺ regulatory T cells control innate immune reactivity after injury. *J Immunol.* 2005;174:2957-2963.
115. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4⁺ T lymphocytes in humans. *J Immunol.* 2001;166:6952-6963.
116. Venet F, Pachot A, Debard AL, et al. Increased percentage of CD4⁺ CD25⁺ regulatory T cells during septic shock is due to the decrease of CD4⁺ CD25 lymphocytes. *Crit Care Med.* 2004;32:2329-2331.
117. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Prevention of lymphocyte cell death in sepsis improves survival in mice. *Proc Natl Acad Sci U S A.* 1999;96:14541-14546.

118. Liaw KY, Askanazi J, Michelson CB, et al. Effect of injury and sepsis on high-energy phosphates in muscle and red cells. *J Trauma*. 1980;20:755-759.
119. Bergstrom J, Bostrom H, Furst P, et al. Preliminary studies of energy-rich phosphagens in muscle from severely ill patients. *Crit Care Med*. 1976;4:197-204.
120. Tresadern JC, Threlfall CJ, Wilford K, Irving MH. Muscle adenosine 5-triphosphate and creatine phosphate concentrations in relation to nutritional status and sepsis in man. *Clin Sci (Lond)*. 1988;75:233-242.
121. Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. *Lancet*. 2002;360:219-223.
122. Fink MP. Bench-to bedside review: cytopathic hypoxia. *Crit Care*. 2002;6:491-499.
123. Sair M, Etherington PJ, Peter Winlove C, Evans TW. Tissue oxygenation and perfusion in patients with systemic sepsis. *Crit Care Med*. 2001;29:1343-1349.
124. Boekstegers P, Weidenhofer S, Pilz G, Werdan K. Peripheral oxygen availability within skeletal muscle in sepsis and septic shock: comparison to limited infection and cardiogenic shock. *Infection*. 1991;19:317-323.
125. Hotchkiss RS, Rust RS, Dence CS, et al. Evaluation of the role of cellular hypoxia in sepsis by the hypoxic marker [18F] fluoromisonidazole. *Am J Physiol*. 1991;261:R965-R972.
126. Bankey PE, Hill S, Geldon D. Sequential insult enhances liver macrophage-signaled hepatocyte dysfunction. *J Surg Res*. 1994;57:185-191.
127. Unno N, Wang H, Menconi MJ, et al. Inhibition of inducible nitric oxide synthase ameliorates endotoxin-induced gut mucosal barrier dysfunction in rats. *Gastroenterology*. 1997;113:1246-1257.
128. Zingarelli B, Day BJ, Crapo JD, Salzman AL, Szabo C. The potential role of peroxynitrite in the vascular contractile and cellular energetic failure in endotoxic shock. *Br J Pharmacol*. 1997;120:259-267.
129. Borutaite V, Brown GC. Rapid reduction of nitric oxide by mitochondria, and reversible inhibition of mitochondrial respiration by nitric oxide. *Biochem J*. 1996;315:295-299.
130. Torres J, Darley-USmar V, Wilson MT. Inhibition of cytochrome c oxidase in turnover by nitric oxide: mechanism and implications for control of respiration. *Biochem J*. 1995;312:169-173.
131. Radi R, Rodriguez M, Castro L, Telleri R. Inhibition of mitochondrial electron transport by peroxynitrite. *Arch Biochem Biophys*. 1994;308:89-95.
132. Szabo C, Zingarelli B, O'Connor M, Salzman AL. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. *Proc Natl Acad Sci U S A*. 1996;93:1753-1758.
133. Khan AU, Delude RL, Han YY, et al. Liposomal NAD(+) prevents diminished O₂ consumption by immunostimulated Caco-2 cells. *Am J Physiol Lung Cell Mol Physiol*. 2002;282:L1082-L1091.
134. Wheeler AP, Bernard GR. Treating patients with severe sepsis. *N Engl J Med*. 1999;340:207-214.
135. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med*. 2001;345:1368-1377.
136. National Heart, Lung, and Blood Institute ARDS Clinical Trials Network; Wheeler AP, Bernard GR, et al. Pulmonary artery versus central venous catheter to guide treatment of acute lung injury. *N Engl J Med*. 2006;354:2213-2224.